{
    "nct_id": "NCT03870399",
    "official_title": "Phase II Study of Hormone Therapy With Tamoxifen in Patients With Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression",
    "inclusion_criteria": "* Age greater than or equal to 18 years\n* Histological diagnosis of well differentiated NET (typical and atypical lung carcinoids, NET G1, NET G2 of all gastroenteropancreatic sites and pancreatic NET G3 according to WHO 2017 classification) 20 advanced / metastatic, inoperable, with no possibility of curative treatment\n* Immunohistochemical expression ≥ 1 percent for estrogen and / or progesterone receptor\n* Disease with radiological progression (at least 10 percent tumor volume growth) in the last 12 months before day 1 cycle 1.\n* No possibility of established treatments due to lack of access, risk of toxicities or without clinical indication. Patients who meet criteria for watchful waiting (low-dose disease and non-functioning NET) may be included.\n* Measurable disease\n* ECOG performance scale 0 to 2.\n* Adequate organic function as defined by the following criteria:\n\n  * serum aspartate aminotransferase (AST), serum alanine aminotransferase (ALT) ≤ 2.5 times the upper limit of local laboratory normality (LSN-LL);\n  * Total serum bilirubin ≤ 2.0 x ULN-LL;\n  * Absolute neutrophil count ≥ 1,500 / mm^3;\n  * Platelet count ≥ 80,000 / mm^3;\n  * Hemoglobin ≥ 9.0 g / dL;\n  * Estimated creatinine clearance by the MDRD equation ≥ 30ml / min\n* Albumin ≥ 3.5 g / dL;\n* INR ≤ 1.5\n* Term of free and informed consent signed by the patient or legal representative.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients already on tamoxifen, but other prior treatment are allowed\n* Patients with aggressive disease requiring cytotoxic therapy or locoregional therapies (eg hepatic embolization)\n* A history of serious clinical or psychiatric illness that, by clinical judgment, may involve participation risk in this study\n* Patients participating in other protocols with experimental drugs.\n* Patients with oral food difficulties.\n* Patients who underwent major recent surgery less than 4 weeks previously.\n* Patients receiving chemotherapy or other oncologic therapy for less than 3 weeks.\n* Patients who use oral anticoagulation\n* Previous history of deep vein thrombosis or pulmonary embolism in the last 12 months.\n* Pregnant or lactating patients.\n* Patients with postmenopausal vaginal bleeding with no defined etiology.\n* Patients with breast cancer who need to use tamoxifen for this neoplasm\n* Another synchronous neoplasm that requires systemic treatment",
    "miscellaneous_criteria": ""
}